Best Health Mutual Funds

Healthcare mutual funds invest primarily in companies operating across the healthcare sector — pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services, and life sciences. Unlike diversified equity funds that spread investments across all sectors, healthcare funds concentrate exclusively on companies developing treatments, devices, and services that address human health needs.

The healthcare sector is one of the largest in the U.S. economy, representing roughly 13–14% of the S&P 500 by weight. Dedicated healthcare funds go much further — holding 80–100% of assets in health-related companies. This concentration means healthcare funds behave differently from the broad market, with returns driven by drug approvals, clinical trial results, regulatory decisions, patent expirations, and demographic trends rather than general economic conditions.

Healthcare funds range from broad-based funds that hold pharmaceutical giants like Johnson & Johnson and Pfizer alongside biotech innovators, to highly focused funds targeting specific sub-sectors like medical devices (FSMEX) or health sciences research (PRHSX). The right choice depends on how much sector-specific risk you're willing to accept and which area of healthcare you find most compelling.

Performance across healthcare funds has diverged sharply depending on sub-sector focus. Here are the standout performers from our database of 5 healthcare-related funds as of June 2026:

Top 1-year returns: - T. Rowe Price Health Sciences (PRHSX): +31.75% — the category leader by a wide margin. PRHSX's diversified healthcare approach — spanning biotech, pharma, med-tech, and healthcare services — captured the sector's broad rally. Active management with a 0.80% expense ratio, $11.1B AUM, and a Morningstar 4-star rating. - Vanguard Health Care Index (VHCIX): +26.69% — the largest and cheapest healthcare fund in our database at $19.0B AUM and just 0.06% ER. Tracks the MSCI US Investable Market Health Care 25/50 Index, providing broad passive healthcare exposure across 400+ stocks.

Underperformers: - Fidelity Select Medical Technology (FSMEX): -2.32% (1yr) — the only healthcare fund in negative territory. FSMEX concentrates narrowly on medical devices and diagnostic technology (Danaher, Thermo Fisher, Intuitive Surgical, Boston Scientific). The medtech sub-sector has lagged the broader healthcare rally as hospital capital spending slowed.

10-year annualized returns: - PRHSX: +9.55% — consistent long-term compounding despite the sector's cyclical volatility. T. Rowe Price's health sciences team has navigated multiple biotech boom-bust cycles. - VHCIX: +9.21% — broad index exposure delivers competitive returns without active manager risk. - FSMEX: +7.77% — medtech's narrower focus has produced lower long-run returns than diversified healthcare, though the 10yr still beats many bond funds.

Key takeaway: Healthcare fund returns vary dramatically by sub-sector. PRHSX's +31.75% vs. FSMEX's -2.32% in the same trailing year illustrates why fund selection matters more in sector funds than in broad equity categories.

Healthcare has structural tailwinds that make it one of the strongest long-term sector investment themes — but it also carries unique risks that investors must understand.

Demographic tailwinds: The global population is aging. In the U.S., 10,000 baby boomers turn 65 every day, driving sustained demand for pharmaceuticals, medical devices, hospital services, and long-term care. By 2030, all baby boomers will be over 65 — the largest elderly cohort in U.S. history. Similar demographic shifts are occurring in Europe, Japan, and China.

Innovation pipeline: The pace of healthcare innovation has accelerated dramatically. GLP-1 drugs (Ozempic, Wegovy, Mounjaro) are the fastest-growing drug class in pharmaceutical history. Gene therapy, mRNA technology (proven during COVID-19), AI-powered drug discovery, and robotic surgery are creating entirely new treatment categories. Companies at the forefront of these innovations can deliver outsized returns — but the R&D path is uncertain and expensive.

Defensive characteristics: Healthcare spending is less sensitive to economic cycles than most sectors. People don't stop taking medications or visiting doctors during recessions. This gives healthcare funds a defensive quality — they tend to fall less than the broad market during downturns, though they also may lag during the strongest bull markets.

The risks: Regulatory and political risk is ever-present. Drug pricing legislation, FDA approval delays, patent cliffs (when blockbuster drugs lose patent protection), and changing insurance reimbursement rates can all impact healthcare company earnings. Biotech companies in particular face binary risk — a single clinical trial result can move a stock 30–50% in either direction.

The healthcare sector is one area where active management has a plausible edge — though index funds remain the lower-risk starting point.

Index fund option: - VHCIX (Vanguard Health Care Index): 0.06% ER — tracks the MSCI US Investable Market Health Care 25/50 Index. Holds 400+ healthcare stocks across all sub-sectors (pharma, biotech, medtech, services). At $19.0B in assets, it's the dominant healthcare index fund. Simple, cheap, diversified within the sector.

Actively managed options: - PRHSX (T. Rowe Price Health Sciences): 0.80% ER — T. Rowe Price's flagship healthcare fund, actively managed since 1995. The management team includes healthcare sector specialists who can evaluate clinical trial data, regulatory pathways, and competitive dynamics that index funds simply own passively. The +31.75% 1yr return vs. VHCIX's +26.69% suggests the active approach can add meaningful value in healthcare. - FSMEX (Fidelity Select Medical Technology): 1.00% ER — narrowly focused on medical devices and diagnostics. This is essentially a sub-sector bet, not a diversified healthcare fund. Suitable only for investors with strong conviction in medtech specifically.

Why active can work in healthcare: Unlike Large Blend where active managers struggle to beat the S&P 500, healthcare has genuine information asymmetry. Evaluating whether a Phase III clinical trial will succeed, or whether a new medical device will gain FDA clearance, requires specialized knowledge. Active managers with deep healthcare expertise — like T. Rowe Price's dedicated health sciences team — can identify winners before the market prices them in.

The practical recommendation: Use VHCIX as a core healthcare holding if you want simple, low-cost sector exposure. Add PRHSX if you believe in active management's ability to pick winners in this research-intensive sector. Avoid FSMEX unless you specifically want concentrated medtech exposure.

Healthcare funds are sector funds — they serve as satellite positions, not core holdings. Understanding how they interact with your existing portfolio is critical.

Sector overlap with broad funds: If you already hold a Total Market fund like VTSAX or FSKAX, roughly 13–14% of your portfolio is already in healthcare stocks. Adding a dedicated healthcare fund like VHCIX doubles down on the sector — which is appropriate if you have conviction but creates concentration risk.

As a satellite position: Most advisors recommend limiting individual sector funds to 5–10% of your total equity allocation. A $500,000 portfolio might hold $25,000–$50,000 in a healthcare fund alongside a diversified core of Large Blend, Total Market, and International funds.

In tax-advantaged accounts: Healthcare funds — especially actively managed ones like PRHSX — are best held in tax-advantaged accounts (401k, IRA, Roth IRA). Active management generates more capital gains distributions than index funds, and the sector's higher turnover creates taxable events that erode returns in taxable accounts.

Not for conservative investors: Healthcare funds carry higher volatility than diversified equity funds. The sector can experience sharp drawdowns during drug pricing scares, regulatory changes, or biotech selloffs. Investors within 5 years of retirement or with low risk tolerance should stick to balanced funds or bond funds rather than sector bets.

Complementary sectors: Investors who hold healthcare as a sector tilt might also consider Technology for growth exposure — the two sectors represent the dominant growth engines of the U.S. economy. Together, tech + healthcare make up roughly 40% of the S&P 500. Our best mutual funds for long-term growth guide covers how to build a growth-oriented portfolio.

Healthcare is not a monolithic sector — it contains several distinct sub-industries with very different risk-return profiles.

Pharmaceuticals — Large drug companies (Pfizer, Merck, Johnson & Johnson, Eli Lilly) that develop, manufacture, and sell branded and generic medicines. Revenue is relatively predictable once drugs are approved, but patent cliffs create periodic earnings drops when blockbuster drugs lose exclusivity. GLP-1 drugs have been a massive tailwind for Eli Lilly and Novo Nordisk.

Biotechnology — Smaller, research-intensive companies developing novel therapies using biological processes (gene therapy, cell therapy, antibody drugs). Biotech offers the highest return potential in healthcare but also the highest risk — many biotech companies have no revenue and depend entirely on clinical trial success. The biotech sub-sector is responsible for most of the sector's extreme return dispersion.

Medical Devices & Diagnostics — Companies like Intuitive Surgical, Medtronic, Danaher, and Boston Scientific that make surgical robots, implants, diagnostic instruments, and testing equipment. Revenue is driven by hospital capital expenditure budgets and surgical procedure volumes. FSMEX focuses on this sub-sector specifically.

Healthcare Services — Hospital operators (HCA Healthcare), pharmacy benefit managers (CVS Health), health insurers (UnitedHealth Group), and healthcare IT companies (Cerner, Veeva Systems). These companies' fortunes are tied to healthcare utilization rates, insurance enrollment, and government reimbursement policies.

Life Sciences Tools — Companies that sell equipment and consumables to pharmaceutical and biotech researchers (Thermo Fisher Scientific, Agilent Technologies). These are the "picks and shovels" of healthcare innovation — they profit regardless of which drugs succeed because all drug companies need their tools.

Broad healthcare funds like VHCIX and PRHSX hold stocks across all these sub-sectors, providing diversified exposure. Narrow funds like FSMEX concentrate in a single sub-sector — higher conviction, higher risk.